Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
| Autor: | Lara Gianesello, Andrew Horton, Vittorio Pavoni |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Arterial thromboembolism Critical Illness Epiphenomenon Disease 030204 cardiovascular system & hematology Article Pathogenesis Antiphospholipid antibodies syndrome 03 medical and health sciences 0302 clinical medicine Critically ill patients Internal medicine Thromboembolism Medicine Animals Humans 030212 general & internal medicine Blood Coagulation Hematology biology business.industry SARS-CoV-2 Incidence (epidemiology) Antiphospholipid antibodies COVID-19 Venous Thromboembolism medicine.disease Thrombosis Coagulation biology.protein Antibodies Antiphospholipid Antibody Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of Thrombosis and Thrombolysis |
| ISSN: | 1573-742X 0929-5305 |
| Popis: | Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. However, it remains uncertain whether aPLs are an epiphenomenon or are involved in the pathogenesis of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink